Eli Lilly and Company (NYSE:LLY) Shares Sold by Red Door Wealth Management LLC

Red Door Wealth Management LLC lowered its stake in Eli Lilly and Company (NYSE:LLY) by 14.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,827 shares of the company’s stock after selling 299 shares during the quarter. Red Door Wealth Management LLC’s holdings in Eli Lilly and Company were worth $1,421,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of LLY. Gotham Asset Management LLC lifted its holdings in Eli Lilly and Company by 111.3% in the third quarter. Gotham Asset Management LLC now owns 7,386 shares of the company’s stock worth $3,967,000 after purchasing an additional 3,891 shares during the period. Logan Capital Management Inc. lifted its holdings in Eli Lilly and Company by 0.9% in the 3rd quarter. Logan Capital Management Inc. now owns 35,290 shares of the company’s stock valued at $18,955,000 after acquiring an additional 302 shares during the last quarter. Hodges Capital Management Inc. acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at about $4,078,000. Insigneo Advisory Services LLC lifted its holdings in Eli Lilly and Company by 16.4% in the 3rd quarter. Insigneo Advisory Services LLC now owns 3,125 shares of the company’s stock valued at $1,679,000 after acquiring an additional 440 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in Eli Lilly and Company by 0.5% in the 3rd quarter. AQR Capital Management LLC now owns 305,633 shares of the company’s stock valued at $164,165,000 after acquiring an additional 1,448 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Argus upped their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Citigroup upped their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, BMO Capital Markets boosted their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $812.72.

Eli Lilly and Company Price Performance

Shares of LLY opened at $905.38 on Monday. The business’s 50-day moving average is $814.40 and its 200-day moving average is $740.86. Eli Lilly and Company has a fifty-two week low of $434.34 and a fifty-two week high of $915.54. The company has a market capitalization of $860.48 billion, a price-to-earnings ratio of 133.34, a P/E/G ratio of 1.97 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the prior year, the company posted $1.62 earnings per share. The firm’s revenue was up 26.0% on a year-over-year basis. Equities research analysts expect that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total value of $1,660,068.00. Following the transaction, the insider now owns 98,554,195 shares in the company, valued at $79,730,343,755. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total value of $1,660,068.00. Following the sale, the insider now directly owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 789,704 shares of company stock worth $672,385,964. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.